Pregabalin Mylan

Country: European Union

Language: Bulgarian

Source: EMA (European Medicines Agency)

Buy It Now

Patient Information leaflet Patient Information leaflet (PIL)
13-01-2023
Summary of Product characteristics Summary of Product characteristics (SPC)
13-01-2023
Public Assessment Report Public Assessment Report (PAR)
19-07-2017

Active ingredient:

прегабалин

Available from:

Mylan Pharmaceuticals Limited

ATC code:

N03AX16

INN (International Name):

pregabalin

Therapeutic group:

Противоэпилептические средства,

Therapeutic area:

Anxiety Disorders; Epilepsy

Therapeutic indications:

Нейропатическая painPregabalin Mylan в е показан за лечение на периферна и Централна нейропатической болка при възрастни. EpilepsyPregabalin Mylan в показан като допълнителна терапия при възрастни с парциальными спазми С или без вторична генерализации. Генерализирана тревожност DisorderPregabalin Mylan в е показан за лечение на генерализирано тревожно разстройство (ГТР) при възрастни.

Product summary:

Revision: 16

Authorization status:

упълномощен

Authorization date:

2015-06-24

Patient Information leaflet

                                65
Б. ЛИСТОВКА
66
ЛИСТОВКА: ИНФОРМАЦИЯ ЗА ПОТРЕБИТЕЛЯ
ПРЕГАБАЛИН MYLAN 25 MG ТВЪРДИ КАПСУЛИ
ПРЕГАБАЛИН MYLAN 50 MG ТВЪРДИ КАПСУЛИ
ПРЕГАБАЛИН MYLAN 75 MG ТВЪРДИ КАПСУЛИ
ПРЕГАБАЛИН MYLAN 100 MG ТВЪРДИ КАПСУЛИ
ПРЕГАБАЛИН MYLAN 150 MG ТВЪРДИ КАПСУЛИ
ПРЕГАБАЛИН MYLAN 200 MG ТВЪРДИ КАПСУЛИ
ПРЕГАБАЛИН MYLAN 225 MG ТВЪРДИ КАПСУЛИ
ПРЕГАБАЛИН MYLAN 300 MG ТВЪРДИ КАПСУЛИ
прегабалин (рregabalin)
_ _
ПРОЧЕТЕТЕ ВНИМАТЕЛНО ЦЯЛАТА ЛИСТОВКА
ПРЕДИ ДА ЗАПОЧНЕТЕ ДА ПРИЕМАТЕ ТОВА
ЛЕКАРСТВО,
ТЪЙ КАТО ТЯ СЪДЪРЖА ВАЖНА ЗА ВАС
ИНФОРМАЦИЯ.
-
Запазете тази листовка. Може да се
наложи да я прочетете отново.
-
Ако имате някакви допълнителни
въпроси, попитайте Вашия лекар или
фармацевт.
-
Това лекарство е предписано лично на
Вас. Не го преотстъпвайте на други
хора. То може
да им навреди, независимо че
признаците на тяхното заболяване са
същите като Вашите.
-
Ако получите някакви нежелани
реакции, уведомете Вашия лекар или
фармацевт. Това
включва и всички възможни нежелани
реакции, неописани в тази листовка.
Вижте
точка 4.
КАКВО СЪДЪРЖА ТАЗИ ЛИСТОВКА
:
1.
Какво представлява Прегабалин Mylan и за
какво се използва
2.
Какво трябва да знаете, преди да
приемете Прегабалин Mylan
3.
Как да приемате Пр
                                
                                Read the complete document

Summary of Product characteristics

                                1
_ _
ПРИЛОЖЕНИЕ I
КРАТКА ХАРАКТЕРИСТИКА НА ПРОДУКТА
2
1.
ИМЕ НА ЛЕКАРСТВЕНИЯ ПРОДУКТ
Прегабалин Mylan 25 mg твърди капсули
Прегабалин Mylan 50 mg твърди капсули
Прегабалин Mylan 75 mg твърди капсули
Прегабалин Mylan 100 mg твърди капсули
Прегабалин Mylan 150 mg твърди капсули
Прегабалин Mylan 200 mg твърди капсули
Прегабалин Mylan 225 mg твърди капсули
Прегабалин Mylan 300 mg твърди капсули
2.
КАЧЕСТВЕН И КОЛИЧЕСТВЕН СЪСТАВ
Прегабалин Mylan 25
mg твърди капсули
Всяка твърда капсула съдържа 25 mg
прегабалин (pregabalin).
Прегабалин Mylan 50
mg твърди капсули
Всяка твърда капсула съдържа 50 mg
прегабалин (pregabalin).
Прегабалин Mylan 75
mg твърди капсули
Всяка твърда капсула съдържа 75 mg
прегабалин (pregabalin).
Прегабалин Mylan 100
mg твърди капсули
Всяка твърда капсула съдържа 100 mg
прегабалин (pregabalin).
Прегабалин Mylan 150
mg твърди капсули
Всяка твърда капсула съдържа 150 mg
прегабалин (pregabalin).
Прегабалин Mylan 200
mg твърди капсули
Всяка твърда капсула съдържа 200 mg
прегабалин (pregabalin).
Прегабалин Mylan 225
mg твърди капсули
Всяка твърда капсула съдържа 225 mg
прегабалин (pregabalin).
Прегабалин Mylan 300
mg твърди капсули
Всяка твърда капсула съдържа 300 mg
прегабалин (pregabalin).
За пълния списък на помощните
вещества вижте т
                                
                                Read the complete document

Similar products

Active ingredient прегабалин

прегабалин

ATC code N03AX16

N03AX16

Marketed by Mylan Pharmaceuticals Limited

Mylan Pharmaceuticals Limited

INN (International Name) pregabalin

pregabalin

Documents in other languages

Patient Information leaflet Patient Information leaflet Spanish 13-01-2023
Summary of Product characteristics Summary of Product characteristics Spanish 13-01-2023
Public Assessment Report Public Assessment Report Spanish 19-07-2017
Patient Information leaflet Patient Information leaflet Czech 13-01-2023
Summary of Product characteristics Summary of Product characteristics Czech 13-01-2023
Public Assessment Report Public Assessment Report Czech 19-07-2017
Patient Information leaflet Patient Information leaflet Danish 13-01-2023
Summary of Product characteristics Summary of Product characteristics Danish 13-01-2023
Public Assessment Report Public Assessment Report Danish 19-07-2017
Patient Information leaflet Patient Information leaflet German 13-01-2023
Summary of Product characteristics Summary of Product characteristics German 13-01-2023
Public Assessment Report Public Assessment Report German 19-07-2017
Patient Information leaflet Patient Information leaflet Estonian 13-01-2023
Summary of Product characteristics Summary of Product characteristics Estonian 13-01-2023
Public Assessment Report Public Assessment Report Estonian 19-07-2017
Patient Information leaflet Patient Information leaflet Greek 13-01-2023
Summary of Product characteristics Summary of Product characteristics Greek 13-01-2023
Public Assessment Report Public Assessment Report Greek 19-07-2017
Patient Information leaflet Patient Information leaflet English 13-01-2023
Summary of Product characteristics Summary of Product characteristics English 13-01-2023
Public Assessment Report Public Assessment Report English 19-07-2017
Patient Information leaflet Patient Information leaflet French 13-01-2023
Summary of Product characteristics Summary of Product characteristics French 13-01-2023
Public Assessment Report Public Assessment Report French 19-07-2017
Patient Information leaflet Patient Information leaflet Italian 13-01-2023
Summary of Product characteristics Summary of Product characteristics Italian 13-01-2023
Public Assessment Report Public Assessment Report Italian 19-07-2017
Patient Information leaflet Patient Information leaflet Latvian 13-01-2023
Summary of Product characteristics Summary of Product characteristics Latvian 13-01-2023
Public Assessment Report Public Assessment Report Latvian 19-07-2017
Patient Information leaflet Patient Information leaflet Lithuanian 13-01-2023
Summary of Product characteristics Summary of Product characteristics Lithuanian 13-01-2023
Public Assessment Report Public Assessment Report Lithuanian 19-07-2017
Patient Information leaflet Patient Information leaflet Hungarian 13-01-2023
Summary of Product characteristics Summary of Product characteristics Hungarian 13-01-2023
Public Assessment Report Public Assessment Report Hungarian 19-07-2017
Patient Information leaflet Patient Information leaflet Maltese 13-01-2023
Summary of Product characteristics Summary of Product characteristics Maltese 13-01-2023
Public Assessment Report Public Assessment Report Maltese 19-07-2017
Patient Information leaflet Patient Information leaflet Dutch 13-01-2023
Summary of Product characteristics Summary of Product characteristics Dutch 13-01-2023
Public Assessment Report Public Assessment Report Dutch 19-07-2017
Patient Information leaflet Patient Information leaflet Polish 13-01-2023
Summary of Product characteristics Summary of Product characteristics Polish 13-01-2023
Public Assessment Report Public Assessment Report Polish 19-07-2017
Patient Information leaflet Patient Information leaflet Portuguese 13-01-2023
Summary of Product characteristics Summary of Product characteristics Portuguese 13-01-2023
Public Assessment Report Public Assessment Report Portuguese 19-07-2017
Patient Information leaflet Patient Information leaflet Romanian 13-01-2023
Summary of Product characteristics Summary of Product characteristics Romanian 13-01-2023
Public Assessment Report Public Assessment Report Romanian 19-07-2017
Patient Information leaflet Patient Information leaflet Slovak 13-01-2023
Summary of Product characteristics Summary of Product characteristics Slovak 13-01-2023
Public Assessment Report Public Assessment Report Slovak 19-07-2017
Patient Information leaflet Patient Information leaflet Slovenian 13-01-2023
Summary of Product characteristics Summary of Product characteristics Slovenian 13-01-2023
Public Assessment Report Public Assessment Report Slovenian 19-07-2017
Patient Information leaflet Patient Information leaflet Finnish 13-01-2023
Summary of Product characteristics Summary of Product characteristics Finnish 13-01-2023
Public Assessment Report Public Assessment Report Finnish 19-07-2017
Patient Information leaflet Patient Information leaflet Swedish 13-01-2023
Summary of Product characteristics Summary of Product characteristics Swedish 13-01-2023
Public Assessment Report Public Assessment Report Swedish 19-07-2017
Patient Information leaflet Patient Information leaflet Norwegian 13-01-2023
Summary of Product characteristics Summary of Product characteristics Norwegian 13-01-2023
Patient Information leaflet Patient Information leaflet Icelandic 13-01-2023
Summary of Product characteristics Summary of Product characteristics Icelandic 13-01-2023
Patient Information leaflet Patient Information leaflet Croatian 13-01-2023
Summary of Product characteristics Summary of Product characteristics Croatian 13-01-2023
Public Assessment Report Public Assessment Report Croatian 19-07-2017

Search alerts related to this product

Alerts Pregabalin Mylan прегабалин

Pregabalin Mylan прегабалин

View documents history

Documents history Documents history

Pregabalin Mylan